Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02713178 · ClinicalTrials.gov registry record · Phase 3

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

A Phase 3 study of Pain, sponsored by Pacira Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
232
Enrollment target
17
Study locations

NCT02713178: Completed Phase 3 study of Pain, sponsored by Pacira Pharmaceuticals.

NCT02713178 is a Phase 3 study of Pain that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 232 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (24% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02713178, a Phase 3 study of Pain, has completed, sponsored by Pacira Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
232 participants
Enrollment target
17
Study locations

Study Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG bupivacaine liposome injectable suspension

Study Locations (17)

Pennsylvania

  • Indiana Regional Medical Center - Indiana
  • Thomas Jefferson University Hospital - Philadelphia
  • Chan Soon-Shiong Medical Center - Windber

Other

  • Ziekenhuis Oost-Limburg - Genk
  • Aarhus University Hospital - Aarhus C
  • Regionshospital Silkeborg - Silkeborg

Florida

  • Jackson Memorial Hospital/University of Miami - Miami
  • Pensacola Research Associates - Pensacola

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Massachusetts General Hospital - Boston

Texas

  • Hermann Drive Surgical Hospital - Houston
  • Westside Surgical Hospital - Houston

Alabama

  • Horizon Research Group, Inc - Mobile

Colorado

  • Denver Metro Orthopedics - Englewood

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2016-06-03
Est. Completion 2017-06-30
Phase Phase 3

Sponsor

Pacira Pharmaceuticals

88 total trials

What the Registry Record Tells You About NCT02713178

The ClinicalTrials.gov registry entry for NCT02713178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (24% lower). The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02713178 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Pennsylvania, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT02713178 about?

NCT02713178 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.

What is the current status of trial NCT02713178?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2016-06-03. Estimated completion is 2017-06-30.

What conditions does trial NCT02713178 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT02713178?

The interventions under investigation include: Placebo (DRUG), bupivacaine liposome injectable suspension (DRUG).

Who is sponsoring clinical trial NCT02713178?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02713178 being conducted?

This trial has 17 study locations across Alabama, Colorado, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.